Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent rhabdomyosarcoma – the most common soft tissue sarcoma of childhood – remains poor, and beyond PAX-FOX01 fusion status, no genomic markers are available for risk stratification. This international consortium study was designed to determine the incidence of driver mutations and their association […]
This Original Investigation from JAMA Network Open assesses whether clinically used markers of breast cancer, such as tumor size, tumor grade, progesterone receptor status, and Ki-67 status, are associated with long-term (25-year) survival as they are with short-term survival. The study was a secondary analysis of data from a subset of 565 women who participated […]
In this JAMA Oncology Narrative Review, the authors attempt to discover whether cardiovascular risks may be associated with the multimodal approach, including systemic therapies and breast radiotherapy (RT), in treating breast cancer patients. Although recent advancements in breast cancer treatment have led to a decrease in mortality rates, the prevalence of survivors with a potentially […]
Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.
US News & World Report recently published its state healthcare rankings, based on three measures: access to healthcare, quality of care, and overall health of the population, measuring rates of obesity, smoking, suicide, mental health, and mortality for adults and infants. At the top, Hawaii was the clear winner. At the bottom, Mississippi. Where does […]
Although initial animal studies indicated this drug might increase the risk of cancer, current research is showing the opposite. In a large systematic review and meta-analysis, for example, researchers showed that patients who took these drugs before their cancer diagnosis had a 21% lower risk of all-cause mortality and a 31% lower risk of cancer-specific […]
According to a study published in The Journal of Physiology in 2020, even passive stretching can provide health benefits. Instead of focusing on peak performance, pushing yourself to the limit, or “feeling the burn,” here are four other exercises that have been scientifically proven to produce serious benefits without a serious commitment.
Getting out and enjoying the sunshine seems to be more important than ever right now, and some studies indicated that not getting enough of vitamin D may be a risk factor for all-cause mortality, and numerous researchers have concluded that we should all probably be getting a little more of it. According to the available […]
Published in Clinical Advances in Hematology & Oncology, this article presents an overview of the currently available monoclonal antibody treatments in multiple myeloma (MM), discussing the clinical value, significant potential, and possible limitations of these immunotherapeutic approaches to driving deeper responses and achieving longer overall survival among patients with a challenging disease.
In this article from MedPage Today, drinking green tea and coffee was associated with reduced all-cause mortality in Japanese patients with type 2 diabetes, especially those who drank both, researchers reported. In a cohort study that followed nearly 5,000 patients for approximately five years, the researchers found a dose-response relationship for both beverages.